877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC
| Autor: | Saba, N.F., Klinghammer, K., Castelluci, E., Colevas, A.D., Rutkowski, T., Thurner, D., Müller-Richter, U., Maio, M., Grewal, J.S., Ottensmeier, C.H.H., Dias, J., Yang, H., Das, R., Furlanetto, J., Herzfeldt, A-K., Kühnle, M-C., Ulges, A., Alles, J., Türeci, Ö., Sahin, U. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S627-S627 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|